Menogaril
Names
Other names
7-O -Methylnogarol
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
UNII
InChI=1S/C28H31NO10/c1-27(36)8-10-6-11-16(21(32)15(10)14(9-27)37-5)22(33)17-13(30)7-12-24(18(17)20(11)31)38-26-23(34)19(29(3)4)25(35)28(12,2)39-26/h6-7,14,19,23,25-26,30,32,34-36H,8-9H2,1-5H3/t14-,19+,23+,25-,26-,27-,28-/m1/s1
N Key: LWYJUZBXGAFFLP-OCNCTQISSA-N
N InChI=1/C28H31NO10/c1-27(36)8-10-6-11-16(21(32)15(10)14(9-27)37-5)22(33)17-13(30)7-12-24(18(17)20(11)31)38-26-23(34)19(29(3)4)25(35)28(12,2)39-26/h6-7,14,19,23,25-26,30,32,34-36H,8-9H2,1-5H3/t14-,19+,23+,25-,26-,27-,28-/m1/s1
Key: LWYJUZBXGAFFLP-OCNCTQISBR
CO[C@@H]1C[C@](C)(O)Cc2cc3c(c(O)c21)C(=O)c1c(O)cc2c(c1C3=O)O[C@@H]1O[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@@H]1O
Properties
Chemical formula
C28 H31 NO10
Molar mass
541.55 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
Menogaril is an anthracycline analog of nogalamycin which was developed in late 1970s. It has even stronger anticancer activity, and less toxicity, than nogalamycin. However, its development for clinical use was cancelled due to only moderate success with relatively high incidence of serious toxicity (43-44% in non-Hodgkin's lymphoma patients).[ 1]
References
^ Moore DF Jr; Brown TD; LeBlanc M; Dahlberg S; Miller TP; McClure S; Fisher RI. (1999). "Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial". Invest New Drugs . 17 (2): 169– 72. doi:10.1023/A:1006375301205 . PMID 10638487 .
Intracellular chemotherapeutic agents / antineoplastic agents (L01)
SPs/MIs (M phase)
Block microtubule assembly Block microtubule disassembly
Taxanes (Cabazitaxel
Docetaxel #
Larotaxel
Ortataxel†
Paclitaxel #
Tesetaxel)
Epothilones (Ixabepilone)
DNA replication inhibitor
DNA precursors/ antimetabolites (S phase)
Folic acid Purine Pyrimidine
DNA polymerase inhibitor (Cytarabine # +daunorubicin)
Deoxyribonucleotide
Topoisomerase inhibitors (S phase)
I
Camptotheca (Belotecan
Camptothecin
Cositecan†
Etirinotecan pegol†
Exatecan
Gimatecan
Irinotecan #
Lurtotecan‡
Rubitecan‡
Silatecan§
Topotecan)
II II+Intercalation
Crosslinking of DNA (CCNS)
Alkylating Platinum-based Nonclassical Intercalation
Photosensitizers/PDT Other
Enzyme inhibitors
FI (Tipifarnib§ )
CDK inhibitors (Abemaciclib
Alvocidib†
Palbociclib
Ribociclib
Seliciclib† )
PrI
PhI (Anagrelide )
IMPDI (Tiazofurin§ )
LI (Masoprocol )
PARP inhibitor (Fuzuloparib
Niraparib +abiraterone acetate
Olaparib
Rucaparib)
HDAC (Belinostat
Entinostat
Panobinostat
Romidepsin
Vorinostat )
PIKI (Pi3K) (Alpelisib
Copanlisib‡
Duvelisib
Idelalisib
Inavolisib
Umbralisib‡ )
IDH (Enasidenib
Ivosidenib
Olutasidenib
Vorasidenib)
Receptor antagonists Other/ungrouped
Adagrasib
Aflibercept
Arsenic trioxide # (Realgar/Indigo naturalis# )
Asparagine depleters (Asparaginase # /Pegaspargase )
Axicabtagene ciloleucel
Belzutifan
Bexarotene
Brexucabtagene autoleucel
Calaspargase pegol
Celecoxib
Ciltacabtagene autoleucel
Darinaparsin
Demecolcine
Denileukin diftitox
Eflornithine
Elesclomol§
Elsamitrucin
Epacadostat
Eribulin
Estramustine
Glasdegib
Idecabtagene vicleucel
Idroxioleic acid
Imetelstat
Lifileucel
Lisocabtagene maraleucel
Lonidamine
Lucanthone
Lurbinectedin
Mitoguazone
Mitotane
Nadofaragene firadenovec
Navitoclax
Nirogacestat
Obecabtagene autoleucel
Oblimersen†
Omacetaxine mepesuccinate
Para-toluenesulfonamide
Pelabresib
Plitidepsin
Retinoids (Alitretinoin
Tretinoin # )
Selinexor
Sitimagene ceradenovec
Sotorasib
Tabelecleucel
Tagraxofusp
Talimogene laherparepvec
Tazemetostat
Tebentafusp
Tiazofurine
Tigilanol tiglate
Tisagenlecleucel
Trabectedin
Veliparib
Venetoclax
Verdinexor
Vosaroxin
# WHO-EM
‡ Withdrawn from market
Clinical trials:
† Phase III
§ Never to phase III